Table 3.

Temporal Trends of Treatments for AMI Patients From 1999 to 2008

	Period 1 (1999–2002) N=32 356	Period 2 (2003–2005) N=34 561	Period 3 (2006–2008) N=41 824
In‐hospital drug use, %
Aspirin	97.4	93.6*	93.7*
Clopidogrel	11.5	69.2*	88.0**
Ticlopidine	31.3	4.7*	1.5**
GP IIbIIIa inhibitor	8.8	17.5*	16.3**
DAPT	39.3	66.1*	82.4**
β‐Blocker	59.0	60.7*	60.1*
ACEI or ARB	73.2	74.0*	72.2**
Statin	18.0	32.7*	45.7**
Four‐combined care	10.4	19.3*	26.5**
In‐hospital procedure or surgery
Ventilator support	4.3	9.5*	9.6**
IABP	3.4	4.8*	6.0**
ECMO	0.1	0.3*	0.7**
PCI	40.6	48.3*	56.2**
CABG	5.9	6.9*	6.4**

Data are presented as N (%). ACEI indicates angiotensin‐converting enzyme inhibitor; AMI, acute myocardial infarction; ARB, angiotensin receptor blocker; CABG, coronary artery bypass graft; DAPT, dual antiplatelet therapy; ECMO, extracorporeal membrane oxygenation; GP, Glycoprotein; IABP, intra‐aortic balloon pumping; PCI, percutaneous coronary intervention.

^*P value (<0.05) compared with Period 2 and Period 1 groups or Period 3 and Period 1 groups using a Student t test or χ² test.

^*P value (<0.05) compared with Period 3 and Period 2 groups using a Student t test or χ² test.